Exopharm Limited, a clinical-stage company based in Melbourne, Australia, is working on developing transformative medicines using extracellular vesicles (EVs). Their technology includes an extracellular vesicle positioning system, leveraging oligonucleotide packing for amplified dosing, and a ligand-based exosome affinity purification. Exopharm's products include Fortrexo CoV for the treatment of SARS-CoV-2 infection, Cognevo for the treatment of neurodegeneration, and PlexoDox for the treatment of cancer. The company is collaborating with Showa Denko Materials Co., Ltd., and was founded in 2013.